FridayFeb 17, 2017 12:10 pm

IntelliPharmaCeutics International, Inc. (NASDAQ: IPCI) Abuse Deterrent Technology featured at Healthcare Conference

The ‘2017 Disruptive Growth & Healthcare Conference’, which ran February 15-16 at the Convene at 730 Third Avenue Conference Center in midtown Manhattan, New York, featured some stellar participants, either as presenters or as sponsors. Along with over 60 other firms in a variety of fields related to biotech, IntelliPharmaCeutics International, Inc. (NASDAQ: IPCI) (TSX: I) was on the bill. The Toronto, Ontario-based company was scheduled to introduce its drug delivery technologies and exhibit its leading pipeline candidates. The ‘2017 Disruptive Growth & Healthcare Conference’ hosted by RHK Capital, which formerly operated as Source Capital Group, was sponsored by leading investor…

Continue Reading

FridayFeb 17, 2017 9:15 am

The Diversification of Auxilio, Inc. (AUXO)

Auxilio, Inc. (NYST MKT: AUXO) is one of a select number of businesses headquartered in Mission Viejo, a mainly residential city in Orange County, California, and a closer look at this small yet booming business shows that it is unique not only for where its offices are based, but also for its value proposition. Auxilio offers managed print services exclusively to the U.S. health care industry. A leader in this sector due to its innovative and customer-driven approach, Auxilio takes full responsibility for its health care clients' on-site print environment through situation assessment, process analysis, strategy development and program implementation.…

Continue Reading

ThursdayFeb 16, 2017 2:55 pm

New Age Beverages Corp. (NASDAQ: NBEV) Announces NASDAQ Capital Market Listing

Colorado-based New Age Beverages Corp. (NASDAQ: NBEV) has priced an underwritten public offering valued at approximately $15 million in gross proceeds and listing on the NASDAQ Capital Market, per a recent press release ( The corporation has also granted underwriters an additional opportunity to purchase 642,857 more shares of common stock. This 45-day option will enable them to purchase the extra shares to cover over-allotments. The total gross proceed amount is an estimate before underwriting discounts, commissions, and other offering expenses are deducted. The company has already filed a registration statement with the Securities and Exchange Commission (SEC). Effective as…

Continue Reading

ThursdayFeb 16, 2017 2:15 pm

Spring Bank Pharmaceuticals (SBPH) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Spring Bank Pharmaceuticals (OTC: SBPH) is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus. SB 9200 has been designed to selectively activate within infected cells the cellular proteins, retinoic acid-inducible gene…

Continue Reading

ThursdayFeb 16, 2017 1:45 pm

Relmada Therapeutics (NYSE: RLMD) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Relmada Therapeutics (NYSE: RLMD) is a clinical-stage biotechnology company focused on developing drugs to treat central nervous system (CNS) diseases, primarily depression and chronic pain in the United States. Its lead product candidate, d-Methadone, is being developed for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER for the management of pain; BuTab ER, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence indications; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful…

Continue Reading

ThursdayFeb 16, 2017 1:40 pm

Singing Machine Company, Inc. (SMDM) Reports 9% Sales Growth for Nine Months, Debuts a Line for Kids

The Singing Machine Company, Inc. (OTCQX: SMDM) recorded revenue growth of 9% to $49.3 million for the nine months ended December 31, 2016, compared to $45.2 million for the comparable period in 2015 ( For the quarter ended December 31, 2016, sales dropped to $16.3 million compared to $20.7 million during the same period of the prior year. The company said that drop was due to the timing of shipments, which occurred earlier in 2016 than the prior year. Singing Machine makes a line of karaoke products, offering the consumer access to some 1,300 songs. The music can either be…

Continue Reading

ThursdayFeb 16, 2017 1:15 pm

KaloBios Pharmaceuticals (KBIO) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

KaloBios Pharmaceuticals (OTC: KBIO) develops monoclonal antibody therapeutics for the treatment of cancer in the United States. Its lead product candidate is benznidazole for the treatment of Chagas disease. The company is also developing proprietary monoclonal antibodies, including lenzilumab, which is in phase I clinical trial in patients with chronic myelomonocytic leukemia; and ifabotuzumab that has completed phase I/II clinical trial in multiple hematologic malignancies, as well as evaluating further studies of ifabotuzumab in rare solid tumors, such as glioblastoma, other brain cancers in children, and rare hematologic cancer indications. For more information, visit the company's website at About…

Continue Reading

ThursdayFeb 16, 2017 12:45 pm

RXi Pharmaceuticals (NASDAQ: RXII) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

RXi Pharmaceuticals (NASDAQ: RXII) is a clinical-stage RNAi company that focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. Its clinical development programs include RXI-109, a self-delivering RNAi compound in phase IIa clinical trial for prevention or reduction of dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids, and in a phase I/II clinical trial in retinal scarring. RXi is also developing RXI-109 for the treatment of an ophthalmic indication, focusing on retinal and corneal scarring; and Samcyprone, in phase II clinical trial for the treatment of…

Continue Reading

ThursdayFeb 16, 2017 12:41 pm

ORhub, Inc. (ORHB) Aims to Cut Annual US Health Care Spending by $250 Billion

ORhub, Inc. (OTC: ORHB), is a cloud-based health care software-as-a-service company whose primary aim is to improve the outcome and reduce costs of surgical care in a variety of hospitals and health care institutions in the United States. Because many hospitals still rely on paper documentation to track everything that occurs during an operation, there is more space for mistakes, missing information, delays, and payment problems, as well as, generally, less opportunity to effectively improve procedures. ORhub’s digital platform eliminates a variety of the limitations and problems inherent with paper documentation. Aside from reducing potential mistakes, the platform creates automatic…

Continue Reading

ThursdayFeb 16, 2017 11:45 am

AudioEye, Inc. (AEYE) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

AudioEye (OTC: AEYE) provides web accessibility solutions to Internet, print, broadcast and other media to people in the United States. The company’s solutions are designed to build accessibility into existing website or web applications; quickly conform to ADA-related standards and best practices; outsource burden of accessibility in time and money-saving manners; and to bridge the gap until accessibility issues can be fixed at the source. The AudioEye Digital Accessibility Platform is designed to be the developer’s comprehensive web accessibility tool. This tool empowers auditors, designers, and developers to understand issues of accessibility and improve website infrastructure through the use of…

Continue Reading

Contact us: 212.418.1217